By the end of week 12, clinical trial participants at the 4mg maintenance dose had lost approximately 12-13% of body weight
A study found 50% to 75% of people who start taking these medications stop using them within a year
Combined with retatrutide driven fat loss, this creates a powerful body recomposition environment
Some studies show there may be a slight effect on GLP-1 levels from green tea, probiotics, and berberine
Unlike many traditional treatments, tirzepatide targets multiple metabolic pathways, harnessing its potential to influence body weight through various mechanisms
While the oral semaglutide formulation Rybelsus has been available for type 2 diabetes, Wegovy as a pill represents the first FDA-approved oral option for obesity, offering patients an alternative to injections and potentially improving long-term treatment adherence